Helicobacter pylori DNA and DNA-associated macromolecules

Helicobacter pylori DNA and DNA-associated macromolecules represent a critical set of therapeutic targets involved in the storage, replication, and expression of the bacterial genome. This target complex includes the double-stranded DNA itself and essential enzymes such as DNA gyrase, topoisomerase IV, and RNA polymerase (StatPearls, 2023). Antimicrobial agents like metronidazole and tinidazole act by undergoing reductive activation to form reactive radicals that cause direct DNA strand breaks and helical destabilization (PubChem). Fluoroquinolones, including levofloxacin and moxifloxacin, target the DNA-associated enzymes gyrase and topoisomerase IV, which are responsible for managing DNA supercoiling and decatenation during replication (PubMed, 2021). Additionally, rifabutin targets the DNA-directed RNA polymerase, effectively blocking the transcription of bacterial genes (NIH, 2022). These interactions are vital for the treatment of H. pylori infections, which are the primary cause of chronic gastritis, peptic ulcer disease, and gastric adenocarcinoma (WHO, 2020). The clinical utility of targeting these molecules is increasingly hampered by the development of resistance, primarily through chromosomal mutations in genes like gyrA and rpoB (Journal of Clinical Medicine, 2020).

Other names

H. pylori genomeH. pylori genetic materialH. pylori DNA replication machineryHelicobacter pylori DNA

DNA strand breakage, Inhibition of DNA gyrase, Inhibition of DNA topoisomerase IV, Inhibition of DNA-directed RNA polymerase